BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 35295612)

  • 41. Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer.
    Klink AJ; Kavati A; Gassama AT; Kozlek T; Gajra A; Antoine R
    Target Oncol; 2022 May; 17(3):321-328. PubMed ID: 35716252
    [TBL] [Abstract][Full Text] [Related]  

  • 42.
    Gambella A; Senetta R; Collemi G; Vallero SG; Monticelli M; Cofano F; Zeppa P; Garbossa D; Pellerino A; Rudà R; Soffietti R; Fagioli F; Papotti M; Cassoni P; Bertero L
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31979374
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer.
    Elfving H; Broström E; Moens LNJ; Almlöf J; Cerjan D; Lauter G; Nord H; Mattsson JSM; Ullenhag GJ; Strell C; Backman M; La Fleur L; Brunnström H; Botling J; Micke P
    Lung Cancer; 2021 Jan; 151():53-59. PubMed ID: 33310622
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
    Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
    [TBL] [Abstract][Full Text] [Related]  

  • 45. NTRK Fusion in a Cohort of BRAF p. V600E Wild-Type Papillary Thyroid Carcinomas.
    Lee SE; Lee MS; Bang H; Kim MY; Choi YL; Oh YL
    Mod Pathol; 2023 Aug; 36(8):100180. PubMed ID: 37003481
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Detection of
    Koopman B; Kuijpers CCHJ; Groen HJM; Timens W; Schuuring E; Willems SM; van Kempen LC
    Diagnostics (Basel); 2022 Mar; 12(3):. PubMed ID: 35328221
    [TBL] [Abstract][Full Text] [Related]  

  • 47. NTRK gene rearrangements are highly enriched in MLH1/PMS2 deficient, BRAF wild-type colorectal carcinomas-a study of 4569 cases.
    Chou A; Fraser T; Ahadi M; Fuchs T; Sioson L; Clarkson A; Sheen A; Singh N; Corless CL; Gill AJ
    Mod Pathol; 2020 May; 33(5):924-932. PubMed ID: 31792356
    [TBL] [Abstract][Full Text] [Related]  

  • 48. GISTs with
    Cao Z; Li J; Sun L; Xu Z; Ke Y; Shao B; Guo Y; Sun Y
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612101
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recurrent
    Khuong-Quang DA; Brown LM; Wong M; Mayoh C; Sexton-Oates A; Kumar A; Pinese M; Nagabushan S; Lau L; Ludlow LE; Gifford AJ; Rodriguez M; Desai J; Fox SB; Haber M; Ziegler DS; Hansford JR; Marshall GM; Cowley MJ; Ekert PG
    Cold Spring Harb Mol Case Stud; 2020 Dec; 6(6):. PubMed ID: 33144287
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
    Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
    Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pan-tropomyosin receptor kinase immunohistochemistry is a feasible routine screening strategy for NTRK fusions in mismatch repair-deficient colorectal carcinomas.
    Zhang Z; Pang J; Chen L; Chen J; Li J; Liu H; Wang J; Wu H; Liang Z
    Hum Pathol; 2022 Nov; 129():21-31. PubMed ID: 35977594
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Practical instructions for testing and targeted therapy in adult patients with solid tumours with NTRK gene fusion in common clinical practice.
    Büchler T; Dundr P; Fínek J; Kiss I; Matěj R; Melichar B; Michal M; Petruželka L
    Klin Onkol; 2020; 33(6):414-419. PubMed ID: 33685189
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach.
    Hernandez S; Conde E; Molero A; Suarez-Gauthier A; Martinez R; Alonso M; Plaza C; Camacho C; Chantada D; Juaneda-Magdalena L; Garcia-Toro E; Saiz-Lopez P; Rojo F; Abad M; Boni V; Del Carmen S; Regojo RM; Sanchez-Frias ME; Teixido C; Paz-Ares L; Lopez-Rios F
    Arch Pathol Lab Med; 2024 Mar; 148(3):318-326. PubMed ID: 37270803
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer.
    Amatu A; Sartore-Bianchi A; Bencardino K; Pizzutilo EG; Tosi F; Siena S
    Ann Oncol; 2019 Nov; 30(Suppl_8):viii5-viii15. PubMed ID: 31738427
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Canadian Multicentric Pan-TRK (CANTRK) Immunohistochemistry Harmonization Study.
    Hyrcza MD; Martins-Filho SN; Spatz A; Wang HJ; Purgina BM; Desmeules P; Park PC; Bigras G; Jung S; Cutz JC; Xu Z; Berman DM; Sheffield BS; Cheung CC; Leduc C; Hwang DM; Ionescu D; Klonowski P; Chevarie-Davis M; Chami R; Lo B; Stockley TL; Tsao MS; Torlakovic E
    Mod Pathol; 2024 Jan; 37(1):100384. PubMed ID: 37972928
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [NTRK Fusions: A new way of treatment for gastro-intestinal tumor?].
    Ouali K; Pellat A; Cohen R; Svrcek M; Penault-Llorca F; André T
    Bull Cancer; 2020 Apr; 107(4):447-457. PubMed ID: 32067719
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.
    Hsiao SJ; Zehir A; Sireci AN; Aisner DL
    J Mol Diagn; 2019 Jul; 21(4):553-571. PubMed ID: 31075511
    [TBL] [Abstract][Full Text] [Related]  

  • 58. TRK Protein Expression in Merkel Cell Carcinoma Is Not Caused by
    Cappellesso R; Nicolè L; Del Fiore P; Barzon L; Sinigaglia A; Riccetti S; Franco R; Zito Marino F; Munari G; Zamuner C; Cavallin F; Sbaraglia M; Galuppini F; Bassetto F; Alaibac M; Chiarion-Sileni V; Piccin L; Benna C; Fassan M; Mocellin S; Dei Tos AP
    Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499693
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunohistochemistry with a pan-TRK antibody distinguishes secretory carcinoma of the salivary gland from acinic cell carcinoma.
    Hung YP; Jo VY; Hornick JL
    Histopathology; 2019 Jul; 75(1):54-62. PubMed ID: 30801752
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Getting Your Laboratory on Track With Neurotrophic Receptor Tyrosine Kinase.
    Eyerer FIR; Bradshaw G; Vasalos P; Laser JS; Chang CC; Kim AS; Olson DR; Paler RJ; Rosenbaum JN; Walk EE; Willis JE; Yao J; Yohe SL
    Arch Pathol Lab Med; 2023 Aug; 147(8):872-884. PubMed ID: 36508682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.